Transcription
The pre-mRNA comprises 19 exons. Coding sequence: 4812 bp.
Protein

Description
LRIG1 is a transmembrane cell-surface protein consisting of 1093 amino acids. LRIG1 contains extracellular part containing 15 leucine-rich repeats (LRR) and three C2-type immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail. LRIG1 can be cut into soluble LRIG1 ectodomain by proteolytic processing, which also is a functional molecule.
Expression
LRIG1 is expressed ubiquitously in various epithelial cells, endothelial cells, heart, smooth and striated muscles, and in large neurons.
Localisation
Differential subcellular distribution in a cell typespecific manner.
Function
LRIG1 acts as a suppressor of receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) family, MET (hepatocyte growth factor receptor), and RET. The interaction of the extracellular LRR domain and immunoglobulin-like domains of LRIG1 with the extracellular parts of the human EGFR results in recruitment of c-Cbl to the cytoplasmic domains, and induction of EGFR degradation. LRIG1 is involved in signal transduction, cell proliferation, cell apopotosis, cell cycle, cell migration, and cell invasion. LRIG1 as a putative tumor suppressor gene often be down-regulated in various human tumors. Soluble ectodomain of LRIG1 protein can modulate EGFR signaling and its growth-promoting activity in a paracrine fashion. 
Implicated in
Ependymoma
Note
Higher cytoplasmic immunoreactivity of LRIG1 correlates with older patient age and higher LRIG1 nuclear immunoreactivity with lower WHO grade.
Prostate cancer
Note High LRIG1 expression is significantly associated with short overall and prostate cancer-specific survival for 256 Swedish patients analysed. In contrast, in the U.S. series, high LRIG1 expression is significantly associated with longer overall survival.
Renal cell carcinoma (RCC)
Note LRIG1 expression is generally downregulated in conventional and papillary RCC but not in chromophobic RCC.
Cutaneous squamous cell carcinoma (SCC)
Note LRIG-1 expression is highest in well-differentiated lesions of cutaneous SCC. LRIG-1 expression intensity of tumor cells is significantly correlated with histologic differentiation of SCC. The SCC patients have significant survival benefits in the high LRIG-1 expression groups compared with low LRIG-1 expression groups.
Breast tumor
Note LRIG1 protein levels are significantly suppressed in the majority of human breast tumors expressing ErbB2.
Cervical squamous cell carcinoma
Note LRIG1 appears to be a significant prognosis predictor in early-stage cervical cancer, independent of the other tumor markers.
Astrocytic tumor
Note
Perinuclear staining of LRIG1 is associated with low WHO grade and better survival of the patients.
Psoriasis
Note
In psoriasis, LRIG1 is mostly absent from the cell surfaces in the spinous layers.
